Home | Doctors | Dr. Ravindra Nandhana

Dr. Ravindra Nandhana

DM Medical Oncology – Tata Memorial Hospital,
Mumbai MD Radiation Oncology, ECMO, PDCR
Designation: Consultant Medical Oncologist and Hemato-Oncologist
Experience: 6 Years

About Doctor:

  • English
  • Telugu
  • Hindi
  • Chemotherapy for Solid tumors
  • Breast cancer, lung cancer, CNS tumors
  • Head and neck cancers
  • Gastrointestinal cancers
  • Genito-urinary cancers
  • Gynecologic cancers
  • Bone cancer and Soft tissue sarcoma
  • Paediatric tumors
  • Hemato-lymphoid malignancies
  • Acute and chronic Leukemias
  • Lymphomas
  • Multiple Myeloma
  • Bone marrow transplantation
  • Immunotherapy
  • Targeted therapy (Precision Oncology)
  • Hormonal therapy for Breast and prostate cancer
  • Procedures
  • PICC line insertion
  • Bone marrow aspiration and biopsy
  • Lumbar puncture and intrathecal therapy
  • Preventive oncology and hereditary cancers
  • Cancer screening
  • Genetic counselling
  • Familial cancer treatment
  • Palliative and supportive care for advanced cancer
  • February 2021 to July 2021 – Worked as Assistant professor (adhoc), Dept of Medical Oncology, MPMMCC & HBCH, Varanasi.
  • August 2020 to January 2021 – Worked as Assistant professor (adhoc), Dept of Medical Oncology, HBCHRC, Visakhapatnam.
  • August 2017 to July 2020 – Senior Residency in Medical Oncology at Tata Memorial Hospital, Mumbai.
  • March 2017 to July 2017 – Consultant Radiation Oncologist at Surya Global Hospital, Kakinada.
  • May 2015 to January 2017 – Senior Resident in Dept of Radiation Oncology at KGH, Visakhapatnam.
  • 2012 to 2015 – Resident in Dept of Radiation Oncology, GSL Medical College, Rajahmundry.
  • Cleared European Society of Medical Oncology (ESMO) examination in 2016, Chennai, India.
  • 2nd prize in Hematology quiz organized by Mumbai Hematology group, 2020.
  • Completed Professional Diploma in Clinical Research (PDCR) examination in January 2021.
  • All India9th rank in DM entrance exam (Medical Oncology), NEET (2017).
  • Secured 99th rank in Engineering and Medical Common Entrance Test (EAMCET) in Andhra Pradesh (2005).
  • Daratumumab and its efficacy in refractory myeloma with anemia.Cancer Res Stat Treat 2020; 3:832-5. DOI: 10.4103/crst.crst_283_20.
  • Pulmonary sarcomatoid carcinoma: Retrospective analysis from a single center. e21188 poster in JCO; https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e21188.
  • Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer.Year: 2020, Volume: 3, Issue: 4, Page: 801-807.DOI: 10.4103/crst.crst_357_20.
  • Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. Published: July 22, 2021. https://doi.org/10.1371/journal.pone.0253722
  • Real world data of treatment free remission in patients with chronic myeloid leukemia (CML) treated at tertiary care oncology Centre from India. 06/12/20; 297883; PB1967
  • European Society of Clinical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)
  • Indian Cooperative Oncology Network (ICON)
  • Association of Radiation Oncologists of India (AROI)
  • AP State Medical Council
Second Opinion
Book Now